PT  - JOURNAL ARTICLE
ED  - ,
TI  - MHRA Drug Safety Update: denosumab (Xgeva) and rebound hypercalcaemia
AID  - 10.1136/dtb.2018.11.000040
DP  - 2018 Dec 01
TA  - Drug and Therapeutics Bulletin
PG  - 142--142
VI  - 56
IP  - 12
4099  - http://dtb.bmj.com/content/56/12/142.short
4100  - http://dtb.bmj.com/content/56/12/142.full
SO  - Drug Ther Bull2018 Dec 01; 56
AB  - Review of: Medical and Healthcare products Regulatory Agency. Denosumab for giant cell tumor of bone: risk of clinically significant hypercalcaemia following discontinuation. Drug Safety Update 2018;11(11);2.